Affordable Access

Access to the full text

Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption

Authors
  • Lin, Qian1, 2
  • Su, Guoqi1, 2
  • Wu, Aimin3
  • Chen, Daiwen1, 2
  • Yu, Bing1, 2
  • Huang, Zhiqing1, 2
  • Luo, Yuheng1, 2
  • Mao, Xiangbing1, 2
  • Zheng, Ping1, 2
  • Yu, Jie1, 2
  • Luo, Junqiu1, 2
  • He, Jun1, 2
  • 1 Sichuan Agricultural University, Chengdu, Sichuan, 611130, People’s Republic of China , Chengdu (China)
  • 2 Key Laboratory for Animal Disease-Resistance Nutrition and Feed, Ministry of Agriculture, Chengdu, Sichuan, 625014, People’s Republic of China , Chengdu (China)
  • 3 South China Agricultural University, Guangzhou, 510642, China , Guangzhou (China)
Type
Published Article
Journal
Antimicrobial Resistance & Infection Control
Publisher
BioMed Central
Publication Date
Nov 26, 2019
Volume
8
Issue
1
Identifiers
DOI: 10.1186/s13756-019-0651-y
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundEnterotoxigenic Escherichia coli (ETEC) is one of the leading bacterial causes of intestinal inflammation and diarrhea. However, the ETEC is frequently resistant to common antibiotics. In this study, we explored the role of a novel antibacterial peptide Bombyx mori gloverin A2 (BMGlvA2) in alleviating ETEC-induced inflammation and intestinal epithelium disruption in mice.MethodsAn ETEC-challenged mice model was used, and the ETEC-challenged mice and non-challenged mice were treated by the BMGlvA2 at different doses.ResultsETEC challenge not only elevated the concentrations of serum inflammatory cytokines such as the IL-6 and TNF-α (P < 0.01), but also elevated the concentrations of serum creatinine and urea (P < 0.05). However, BMGlvA2 attenuated the inflammatory responses by decreasing the serum inflammatory cytokines and improving the metabolisms in ETEC-challenged mice, and alleviated the ETEC-induced tissue damage in spleen. Moreover, BMGlvA2 treatment significantly elevated the duodenum villus height and decreased the crypt depth in the duodenum and ileum in ETEC-challenged mice (P < 0.05). Interestingly, BMGlvA2 improved the distribution and abundance of tight-junction protein ZO1 in duodenum and ileum epithelium after ETEC-challenge. Moreover, BMGlvA2 significantly down-regulated the expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and the apoptosis-related genes (Caspase 8 and Caspase 9) in jejunal mucosa (P < 0.05) in the TETC-challenged mice. Importantly, BMGlvA2 significantly elevated the expression levels of critical genes related to mucosal barrier functions such as the mucins (MUC1 and MUC2) and glucose transporter (GLUT2) in the intestinal mucosa (P < 0.05).ConclusionOur results suggested a novel function of the conventional antibacterial peptides, and the anti-bacterial and anti-inflammatory properties of BMGlvA2 may allow it a potential substitute for conventionally used antibiotics or drugs.

Report this publication

Statistics

Seen <100 times